St Paul's Hospital, Vancouver BC, Canada.
University of British Columbia, Vancouver BC, Canada.
Can J Gastroenterol Hepatol. 2016;2016:1651570. doi: 10.1155/2016/1651570. Epub 2016 Dec 7.
Crohn's disease (CD) is a complex disorder with important incidence in North America. Perianal fistulas occur in about 20% of patients with CD and are almost always classified as complex fistulas. Conventional treatment options have shown different success rates, yet there are data indicating that these approaches cannot achieve total cure and may not improve quality of life of these patients. Fibrin glue, fistula plug, topical tacrolimus, local injection of infliximab, and use of hematopoietic stem cells (HSC) and mesenchymal stem cells (MSC) are newly suggested therapies with variable success rates. Here, we aim to review these novel therapies for the treatment of complex fistulizing CD. Although initial results are promising, randomized studies are needed to prove efficacy of these approaches in curing fistulizing perianal CD.
克罗恩病（CD）是一种复杂的疾病，在北美有重要的发病率。肛周瘘管在约 20%的 CD 患者中发生，几乎总是被归类为复杂瘘管。传统的治疗选择显示出不同的成功率，但有数据表明，这些方法不能达到完全治愈的效果，也不能改善这些患者的生活质量。纤维蛋白胶、瘘管塞、局部他克莫司、局部注射英夫利昔单抗、以及使用造血干细胞（HSC）和间充质干细胞（MSC）是新提出的具有不同成功率的治疗方法。在这里，我们旨在综述这些用于治疗复杂瘘管性 CD 的新疗法。尽管初步结果很有希望，但需要进行随机研究来证明这些方法在治愈肛周瘘管性 CD 方面的疗效。
